CDK4 and breast cancer: Similar trends were observed in HR + BC patients who were treated with the aromatase inhibitor exemestane (Additional file 2: Fig. S1C, p = 0.0015) and CDK4/6 inhibitor palbociclib (Additional file 2: Fig. S1D, p = 0.023).